The malignant ascites pipeline possesses only two drugs in
mid-stage developments to be approved in the near future. The major
key players include Clover Biopharmaceuticals and Wuhan YZY
Biopharma which hold the potential to create a significant positive
shift in the malignant ascites market size.
LAS
VEGAS, April 29, 2024 /PRNewswire/ --
DelveInsight's Malignant Ascites Market Insights report
includes a comprehensive understanding of current treatment
practices, malignant ascites emerging drugs, market share of
individual therapies, and current and forecasted market size from
2020 to 2034, segmented into 7MM [the
United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Malignant Ascites Market
Report
- According to DelveInsight's analysis, the market size for
malignant ascites reached USD 1.9
billion in 2020 across the 7MM, which is anticipated to
rise to USD 2.3 billion by
2034.
- In 2020, the total incident cases of malignant
ascites-associated cancers were ~1.6 million in the
7MM.
- Leading malignant ascites companies such as LINDIS
BIOTECH, WUHAN YZY BIOPHARMA CO.,
LTD., CLOVER BIOPHARMACEUTICALS, BINHUI BIOPHARMACEUTICAL,
PHARMACYTE BIOTECH INC., and others are developing novel
malignant ascites drugs that can be available in the malignant
ascites market in the coming years.
- The promising malignant ascites therapies in the pipeline
include CATUMAXOMAB, M 701, SCB-313, VAK, and CYPSCAPS
PLUS IFOSFAMIDE, among others.
- Wuhan YZY Biopharma's M701 is the first and only
EpCAM × CD3 BsAb that has entered into a Phase II clinical trial
for the treatment of M701 globally.
- Even with the new therapies coming in the market, still the
mainstay treatment for Malignant Ascites will remain chemotherapy
over the years. Out of the novel treatments, the highest revenue is
expected to be generated by CATUMAXOMAB with 10.54% of share
of the total market in 2034, followed by KM-CART with 5.07%
and OK-432 with 2.21% of market share, respectively.
Discover which therapies are expected to grab the major
malignant ascites market share @ Malignant Ascites Market
Report
Malignant Ascites Overview
Malignant ascites is a pathological condition stemming from
various primary abdominal and non-abdominal cancers. It stands as a
significant source of illness, presenting numerous complexities and
treatment obstacles. It serves as an indicator of peritoneal
carcinomatosis, denoting the presence of cancerous cells within the
peritoneal cavity. Carcinomatosis-causing tumors are frequently
secondary malignancies affecting the peritoneal surface, such as
those from ovarian, colorectal, pancreatic, and uterine origins; as
well as extraperitoneal tumors originating from lymphoma, lung, and
breast cancers, alongside smaller proportion of unidentified
primary tumors.
The origins of fluid accumulation within the abdomen are diverse
and may include cirrhosis, congestive heart failure, nephrosis,
pancreatitis, peritonitis, primary malignancies, or liver
metastases. Differentiating between benign and malignant ascites
solely through physical examination or radiographic methods is not
feasible. Invasive procedures are required to distinguish between
the two types. Ascitic fluid analysis through abdominal
paracentesis can typically identify malignant causes of ascite
production; however, laparoscopic tissue sampling might be
necessary in certain cases.
Malignant Ascites Epidemiology Segmentation
The malignant ascites epidemiology section provides insights
into the historical and current malignant ascites patient pool and
forecasted trends for the 7MM. It helps recognize the causes of
current and forecasted patient trends by exploring numerous studies
and views of key opinion leaders.
The malignant ascites market report proffers
epidemiological analysis for the study period 2020–2034 in the 7MM
segmented into:
- Total Incident Cases of Ascites in Selected Indications
(Ovarian, Colorectal, Gastric, and Others)
- Incident Cases of Malignant Ascites in Selected
Indications
- Total Treated Cases of Malignant Ascites
Malignant Ascites Treatment Market
The available treatments for malignant ascites consist of
various strategies designed to ease symptoms and enhance quality of
life. These methods include draining fluids through paracentesis,
using chemotherapy to combat cancer cells and lessen ascite
formation, employing targeted therapy tailored to particular cancer
types, opting for surgical procedures like tumor removal or shunt
insertion, and incorporating supportive measures such as diuretics
and nutritional assistance. The selection of treatment is
determined by factors such as the specific cancer type and the
severity of symptoms, with the main objective being the management
of symptoms and the improvement of overall well-being.
Malignant ascite treatments aimed at causing a reduction in
malignant ascites mainly consist of systemic chemotherapy, targeted
therapy, or surgical procedures designed to decrease or remove the
cancerous tumors accountable for the development of ascites. These
methods focus on the fundamental cause of ascites by dealing with
the underlying cancer, intending to slow down the advancement of
the disease and enhance the outcomes for the patient.
With just two accepted treatments, OK-432 and KM-CART,
available in Japan, many patients
are left with only palliative care, which often falls short of
addressing their needs. Various methods exist to relieve symptoms
linked with malignant ascites. However, due to a lack of
understanding of ascites' natural progression, there is limited
data on these approaches and their impact on quality of life.
Assessing the effectiveness of current treatments is challenging.
Common traditional methods for handling malignant ascites encompass
sodium-restricted diets, diuretic treatment, repeated paracentesis,
and peritoneovenous shunting.
To know more about malignant ascites treatment guidelines, visit
@ Malignant Ascites Management
Malignant Ascites Pipeline Therapies and Key
Companies
- CATUMAXOMAB: LINDIS BIOTECH
- M 701: WUHAN YZY BIOPHARMA
CO., LTD.
- SCB-313: CLOVER BIOPHARMACEUTICALS
- VAK: BINHUI BIOPHARMACEUTICAL
- CYPSCAPS PLUS IFOSFAMIDE: PHARMACYTE BIOTECH INC.
Learn more about the FDA-approved drugs for malignant ascites @
Drugs for Malignant Ascites Treatment
Malignant Ascites Market Dynamics
The dynamics of the malignant ascites market are expected to
change in the coming years. SCB-313 utilizes distinctive,
patented protein trimerization technology to precisely target and
activate the triple-dependent mechanism of tumor cell apoptosis,
fostering collaboration among oncologists, surgeons, researchers,
and other healthcare professionals to develop effective
management strategies, identification of novel therapeutic
targets through advanced molecular analyses, and an emphasis on
patient-centered care and improved symptom management to enhance
the overall quality of life for patients with malignant
ascites.
Furthermore, many potential therapies are being investigated for
the treatment of malignant ascites, and it is safe to predict that
the treatment space will significantly impact the malignant
ascites market during the forecast period. Moreover, the
anticipated introduction of emerging therapies with improved
efficacy and a further improvement in the diagnosis rate are
expected to drive the growth of the malignant ascites market
in the 7MM.
However several factors may impede the growth of the malignant
ascites market. Tackling malignant ascites poses ongoing
difficulties in clinical management, with the current focus
primarily on alleviating symptoms rather than achieving a
definitive cure, due to the absence of universally accepted
treatment protocols stemming from limited evidence and
patient heterogeneity; consequently, malignant ascites also
presents research obstacles, with only a few attempts made to
develop medications for the condition, and the potential
hindrance of access to emerging therapies once approved by the
availability of off-label therapies.
Moreover, malignant ascites treatment poses a
significant economic burden and disrupts patients' overall
well-being and QOL. Furthermore, the malignant ascites market
growth may be offset by failures and discontinuation of emerging
therapies, unaffordable pricing, market access and
reimbursement issues, and a shortage of healthcare
specialists. In addition, the undiagnosed, unreported cases
and the unawareness about the disease may also impact the
malignant ascites market growth.
Malignant Ascites
Market Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Malignant Ascites
Market CAGR
|
1.2 %
|
Malignant
Ascites Market Size in
2020
|
USD 1.9
Billion
|
Key Malignant Ascites
Companies
|
LINDIS BIOTECH, WUHAN
YZY BIOPHARMA CO., LTD., CLOVER BIOPHARMACEUTICALS, BINHUI
BIOPHARMACEUTICAL, PHARMACYTE BIOTECH INC., and others
|
Key Pipeline Malignant Ascites Therapies
|
CATUMAXOMAB, M 701,
SCB-313, VAK, CYPSCAPS PLUS IFOSFAMIDE, and others
|
Scope of the Malignant Ascites Market
Report
- Therapeutic Assessment: Malignant Ascites current
marketed and emerging therapies
- Malignant Ascites Market Dynamics: Key
Market Forecast Assumptions of Emerging Malignant Ascites Drugs and
Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Malignant Ascites
Market Access and Reimbursement
Discover more about malignant ascites drugs in development
@ Malignant Ascites Clinical Trials
Table of Contents
1
|
KEY INSIGHTS
|
2
|
REPORT
INTRODUCTION
|
3
|
EXECUTIVE SUMMARY OF
MALIGNANT ASCITES
|
4
|
MALIGNANT ASCITES
MARKET OVERVIEW AT A GLANCE
|
4.1
|
MARKET SHARE BY
THERAPIES (%) DISTRIBUTION OF MALIGNANT ASCITES IN 2020 IN THE
7MM
|
4.2
|
MARKET SHARE BY
THERAPIES (%) DISTRIBUTION OF MALIGNANT ASCITES IN 2034 IN THE
7MM
|
5
|
KEY EVENTS
|
6
|
MALIGNANT ASCITES:
DISEASE BACKGROUND AND OVERVIEW
|
6.1
|
INTRODUCTION
|
6.2
|
SIGN AND
SYMPTOMS
|
6.3
|
PATHOPHYSIOLOGY
|
6.3.1
|
Peritoneal
Physiology
|
6.3.2
|
Pathophysiology of
Malignant Ascites
|
6.4
|
DIAGNOSIS
|
6.5
|
TREATMENT
MANAGEMENT
|
6.5.1
|
Paracentesis
|
6.5.2
|
Peritoneovenous
Shunts
|
6.5.3
|
Diuretics
|
6.5.4
|
Drainage
Catheters
|
7
|
EPIDEMIOLOGY AND
PATIENT POPULATION
|
7.1
|
KEY FINDINGS
|
7.2
|
ASSUMPTIONS AND
RATIONALE
|
7.3
|
TOTAL INCIDENT CASES OF
MALIGNANT ASCITES ASSOCIATED CANCERS IN THE 7MM
|
7.4
|
TOTAL PATIENT POOL OF
MALIGNANT ASCITES IN THE 7MM
|
7.5
|
THE UNITED
STATES
|
7.5.1
|
Total Incident Cases of
Malignant Ascites Associated Cancers in the US
|
7.5.2
|
Total Patient Pool of
Malignant Ascites in the US
|
7.6
|
EU4 AND THE
UK
|
7.6.1
|
Total Incident Cases of
Malignant Ascites Associated Cancers in EU4 and the UK
|
7.6.2
|
Total Patient Pool of
Malignant Ascites in EU4 and the UK
|
7.7
|
JAPAN
|
7.7.1
|
Total Incident Cases of
Malignant Ascites Associated Cancers in Japan
|
7.7.2
|
Total Patient Pool of
Malignant Ascites in Japan
|
8
|
PATIENT
JOURNEY
|
9
|
MARKETED
DRUGS
|
9.1
|
OK-432:
ROCHE
|
9.1.1
|
Product
Description
|
9.1.2
|
Regulatory
Milestones
|
9.1.3
|
Others Developmental
Activities
|
9.1.4
|
Safety and
Efficacy
|
9.1.5
|
Product
Profile
|
9.2
|
KM-CART: ASAHI KASEI
MEDICAL CO. LTD.
|
9.2.1
|
Product
Description
|
9.2.2
|
Regulatory
Milestones
|
9.2.3
|
Safety and
Efficacy
|
9.2.4
|
Product
Profile
|
10
|
EMERGING
DRUGS
|
10.1
|
KEY
COMPETITORS
|
10.2
|
CATUMAXOMAB: LINDIS
BIOTECH
|
10.2.1
|
Product
Description
|
10.2.2
|
Other Developmental
Activities
|
10.2.3
|
Clinical
Development
|
10.2.3.1
|
Clinical Trials
Information
|
10.2.4
|
Safety and
Efficacy
|
10.3
|
M 701: WUHAN YZY
BIOPHARMA CO., LTD.
|
10.3.1
|
Product
Description
|
10.3.2
|
Other Developmental
Activities
|
10.3.3
|
Clinical
Development
|
10.3.3.1
|
Clinical Trials
Information
|
10.3.4
|
Safety and
Efficacy
|
10.4
|
SCB-313: CLOVER
BIOPHARMACEUTICALS
|
10.4.1
|
Product
Description
|
10.4.2
|
Other Developmental
Activities
|
10.4.3
|
Clinical
Development
|
10.4.3.1
|
Clinical Trials
Information
|
10.4.4
|
Safety and
Efficacy
|
10.5
|
VAK: BINHUI
BIOPHARMACEUTICAL
|
10.5.1
|
Product
Description
|
10.5.2
|
Clinical
Development
|
10.5.2.1
|
Clinical Trials
Information
|
10.6
|
CYPSCAPS PLUS
IFOSFAMIDE: PHARMACYTE BIOTECH INC.
|
10.6.1
|
Product
Description
|
10.6.2
|
Other Developmental
Activities
|
10.6.3
|
Safety and
Efficacy
|
11
|
MALIGNANT ASCITES:
MARKET ANALYSIS
|
11.1
|
KEY FINDINGS
|
11.2
|
MARKET
OUTLOOK
|
11.3
|
TOTAL MARKET SIZE OF
MALIGNANT ASCITES IN THE 7MM
|
11.4
|
UNITED STATES MARKET
SIZE
|
11.4.1
|
Total Market Size of
Malignant Ascites in the United States
|
11.4.2
|
Market Size of
Malignant Ascites by Therapies in the United States
|
11.5
|
EU4 AND THE UK MARKET
SIZE
|
11.5.1
|
Total Market Size of
Malignant Ascites in EU4 and the UK
|
11.5.2
|
Market Size of
Malignant Ascites by Therapies in EU4 and the UK
|
11.6
|
JAPAN MARKET
SIZE
|
11.6.1
|
Total Market Size of
Malignant Ascites in Japan
|
11.6.2
|
Market Size of
Malignant Ascites by Therapies in Japan
|
12
|
UNMET NEEDS
|
13
|
SWOT
ANALYSIS
|
14
|
KOL VIEWS
|
15
|
MARKET ACCESS AND
REIMBURSEMENT
|
15.1
|
UNITED
STATES
|
15.1.1
|
Center for Medicare
& Medicaid Services (CMS)
|
15.1.2
|
Zero Dollar Copay
(ZDC)
|
15.2
|
EU4 AND THE
UK
|
15.2.1
|
Germany
|
15.2.2
|
France
|
15.2.3
|
Italy
|
15.2.4
|
Spain
|
15.2.5
|
United
Kingdom
|
15.3
|
JAPAN
|
15.3.1
|
MHLW
|
16
|
APPENDIX
|
16.1
|
BIBLIOGRAPHY
|
16.2
|
REPORT
METHODOLOGY
|
17
|
DELVEINSIGHT
CAPABILITIES
|
18
|
DISCLAIMER
|
19
|
ABOUT
DELVEINSIGHT
|
Related Reports
Malignant Ascites Pipeline
Malignant Ascites Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key malignant ascites companies,
including Clover Biopharmaceuticals, YZY Biopharma, Sorrento
Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, among others.
Malignant Ascites Epidemiology Forecast
Malignant Ascites Epidemiology Forecast –
2032 report delivers an in-depth understanding of the
disease, historical and forecasted malignant
ascites epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy,
France, and the United Kingdom), and Japan.
Ascites Market
Ascites Market Insights, Epidemiology, and Market Forecast –
2032 report delivers an in-depth understanding of the disease,
historical and forecasted epidemiology, as well as the market
trends, market drivers, market barriers, and key
ascites companies, including Grifols Therapeutics LLC,
Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen
Ltd, Healthgen Biotechnology Corp, Sichuan Clover
Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc,
Novartis, among others.
Ascites Pipeline
Ascites Pipeline Insight – 2024 report provides
comprehensive insights about the pipeline landscape, pipeline drug
profiles, including clinical and non-clinical stage products, and
the key ascites companies, including Grifols Therapeutics
LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V,
Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover
Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc,
Novartis, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/malignant-ascites-market-to-observe-growth-at-a-cagr-of-1-2-by-2034--delveinsight-302129898.html
SOURCE DelveInsight Business Research, LLP